Medgenics to Present at Rodman & Renshaw 4th Annual Global Healthcare Conference.

CEO to Share Clinical Proof of Principle and Development Strategy

KARMIEL, Israel -- Medgenics Inc. announced that Andrew L. Pearlman, Ph.D., President and CEO, is scheduled to present at the Rodman & Renshaw 4th Annual Global Healthcare Conference. The conference will be held May 14 - 15 at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco. Dr. Pearlman will present on Tuesday May 15th at 3:15 p.m. in the Atlantique Salon.

A live webcast of Medgenics' presentation can be accessed by logging onto http://www.rodmanandrenshaw.com/Conferences.asp?CID=conf20&ACT=confweb casters&BGCOLOR=wht (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.).

Medgenics is developing a biological pump, the Biopump, made using a patient's own skin, as an alternative to today's protein therapy, which involves frequent bolus injections of proteins. Directly addressing the majority of the $51 billion market for injected proteins, the Biopump works inside a patient's body to produce and deliver the active protein steadily for a sustained duration in order to treat a targeted indication.

The Company is developing two products based on its sustained-action Biopump technology: EPODURE producing erythropoietin (EPO) to treat anemia, and INFRADURE producing interferon-alpha (IFN-a) to treat hepatitis C. Medgenics plans to commence formal efficacy trials for EPODURE in the first quarter of 2008.

Medgenics has demonstrated proof-of-principle of the Biopump to deliver EPO to anemic patients in a clinical trial. The trial also demonstrated proof-of-principle for the method of converting human dermal cores into mini protein production plants and indicated that implantation of the dermal cores back into the same patients could safely and significantly increase the patient's level of protein on a short-term basis. Medgenics' testing to date has shown the Biopump EPO to be dose-controlled, reproducible, and free of significant adverse effects, as well as capable of promoting patient compliance. Although short by design, this trial provided critical proof-of-principle data for the prototype devices used to harvest and implant the Biopump. Recent advances with a "gutless" adeno vector are expected to enable sustained-action Biopumps to provide at least four to six months of high level protein delivery.

About Medgenics

Medgenics Inc. is a biopharmaceutical company developing a platform technology to provide sustained-action protein therapy for the treatment of a range of diseases, starting with anemia and hepatitis C. Medgenics has already shown proof-of-principle of the Biopump to deliver erythropoietin (EPO) in a clinical trial to anemic patients. The Company is developing two products based on its sustained-action Biopump technology: EPODURE producing EPO to treat anemia, and INFRADURE producing interferon-alpha (IFN-a) to treat hepatitis C. For more information visit www.medgenics.com.

This news release contains certain forward-looking statements that involve risks and uncertainties. Such statements are only predictions and the company's actual results may differ materially from those anticipated in these forward-looking statements. Factors that may cause such differences include the timing of clinical trials, the risk that products that appeared promising in early research and clinical trials do not demonstrate safety or efficacy in clinical trials and the risk that the company will not obtain approval to market its products.